Approximately 1% of the global population suffers from a protein disease, an autoimmune disorder that causes damage to small intestines when a person delivers a gluten. But new treatment is currently Phase II clinical trials can change everything that enables people to enter the disorder during their diets.
Celick disease is hereditary and leads to an immune system that reacts to gluten containing wheat, barley and rye proteins. For the reasons that are not completely thought out, gluten ingesting makes the body's intestine as strangers and attacks on the inflammatory reaction.
Besides the intestinal damage, the immune response also blocks nutrients that are absorbed properly in the body. Other symptoms include abdominal pain, abdomen, diarrhea, constipation, headache, bone pain and chronic fatigue.
Now, the only thing a person with a chicken disease can stay safe is to remove the gluten entirely from their diet. The disorder is so hard that the number of wheat or rye may cause immune reaction. In the future, people with protein disease can have a normal life through innovative new treatments.
<! – Keywords: zmescience_300x250_InContent
The difference between celiac disease and gluten intolerance
There is a difference in celiac disease (CD) and gluten intolerance. Things are even harder if you add a gluten allergy mix, which is another clear condition related to gluten.
Unlike Celiac disease, both gluten sensitivity and gluten intolerance do not cause growth in the small intestine. The body, however, identifies gluten as an alien invader that causes the immune response. Unfortunately, 83% of people with protein disease are either untraceable or incorrect because symptoms and symptoms are otherwise different.
Nexvax2 is a vaccine that protects people with celiac disease, which can prevent intuitivative gluten and provide unlimited diet for patients. The vaccine is specifically designed against the gene HLA-DQ2.5 gene, which is 90% of celiac.
According to Nexvax2's manufacturer ImmusanT, the vaccine is inserted into multiple doses that reprogram T-cells will stop prosthetic reaction reactions.
In September, the first patient received a vaccine dose. Now, Immusant begins Phase II Clinical Study involving 150 participants in the US, Australia and New Zealand. During 16 weeks the researchers will stabilize the vaccine dose to maintain stability in patients with gluten proteins.
Phase II courts usually last for about two years. If all goes well, the therapy is in phase III, where researchers should demonstrate that the vaccine is still safe and effective as the current parameters. Ultimately, if the treatment is undergoing this phase, it can appeal to the FDA to make it available to patients in the United States.
Enjoy this article? Join 40,000+ subscribers for the ZME Science Bulletin. Subscribe now!